1492 Capital Management’s Viking Therapeutics VKTX Stock Holding History

1492 Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.17M	Buy	55,723 +14,542	+35%	+$470K	0.64%	49
2026 Q1	$1.34M	Sell	41,181 -41	-0.1%	-$1.32K	0.51%	61
2025 Q4	$1.45M	Sell	41,222 -4	-0%	-$142	0.56%	56
2025 Q3	$1.08M	Buy	41,226 +216	+0.5%	+$6.44K	0.44%	67
2025 Q2	$1.09M	Sell	41,010 -48	-0.1%	-$1.26K	0.5%	67
2025 Q1	$992K	Buy	+41,058	New	+$1.3M	0.53%	55

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

1492 Capital Management's VKTX Position: Q2 2026 in Review

1492 Capital Management increased its Viking Therapeutics (VKTX) stake by 35% in Q2 2026, buying an estimated $470K and bringing the position to 55,723 shares worth $2.17M. The position accounts for 0.64% of the portfolio, ranked #49.

1492 Capital Management first reported a position in VKTX in Q1 2025 and has held it in 6 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

1492 Capital Management held 55,723 shares of Viking Therapeutics worth $2.17M as of Q2 2026.
1492 Capital Management bought 14,542 Viking Therapeutics shares in Q2 2026, an estimated $470K.
Viking Therapeutics made up 0.64% of 1492 Capital Management's portfolio in Q2 2026, its #49 holding.
1492 Capital Management first reported a position in Viking Therapeutics in Q1 2025 and has held it in 6 quarters since.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on 1492 Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.